Treatment-emergent anemia (CALR: 35.7% versus JAK2: 30.4%, p = 0.37), overall and treatment-emergent thrombocytopenia were comparable in the two groups (p = 0.49 and p = 0.60, respectively). This evidence concerns the gene JAK2 and anemia (phenotype).